Aptus is developing an Endovascular AAA Repair System, which includes both the Endograft and the EndoStapling System and provides a durable alternative to open surgical repair by separating the functions of aneurysm exclusion and endograft fixation.
Aptus said that the proceeds from the financing, led by US Venture Partners and Longitude Capital, will be used to advance clinical and commercial development in Europe and continue the US regulatory processes related to the Aptus EndoStapling System as both a stand-alone product and as part of the Aptus Endovascular AAA Repair System.
Aptus CEO Jeff Elkins said that subsequent to completing first series of EndoStapling System cases in Europe, they are pleased to receive additional financial support from venture capital investors and their continued support reflects the strong interest in technology.
“We look forward to accelerating our clinical and commercial efforts in order to bring our novel Aptus Endograft and EndoStapling System to patients in need of low profile delivery without compromises in device design, fixation, and treatment durability,” Elkins said.
